Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192
Top Cited Papers
Open Access
- 2 January 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 56 (1), 323-333
- https://doi.org/10.1002/art.22289
Abstract
Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). Methods Patients with SSc duration of P = 0.0008). Changes in the PINP level from baseline correlated with changes in the MRSS (r = 0.37, P = 0.027). Conclusion We report the first evaluation of a systemically administered and repeatedly dosed anti‐TGFβ1 drug. In this pilot study, CAT‐192, in doses up to 10 mg/kg, showed no evidence of efficacy. The utility of clinical and biochemical outcome measures and the feasibility of multicenter trials of early dcSSc were confirmed.Keywords
This publication has 34 references indexed in Scilit:
- Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor-β Receptor (TβRIIΔk)Published by Elsevier BV ,2005
- Scleroderma—clinical and pathological advancesBest Practice & Research Clinical Rheumatology, 2004
- A modified model of graft‐versus‐host–induced systemic sclerosis (scleroderma) exhibits all major aspects of the human diseaseArthritis & Rheumatism, 2004
- Latency-Associated Peptide Prevents Skin Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human SclerodermaJournal of Investigative Dermatology, 2003
- Smad7 Inhibits Fibrotic Effect of TGF-β on Renal Tubular Epithelial Cells by Blocking Smad2 ActivationJournal of the American Society of Nephrology, 2002
- Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesisCurrent Opinion in Rheumatology, 2001
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Autocrine Overexpression of CTGF Maintains Fibrosis: RDA Analysis of Fibrosis Genes in Systemic SclerosisExperimental Cell Research, 2000
- Expression of TGF-β1, -β2 and -β3 in localized and systemic sclerodermaJournal of Dermatological Science, 1999